Jay Gibbons

1.9k citations

14 papers · 1.5k indexed · h-index 11

Hematology top 5%
Cancer Research top 10%
Molecular Biology top 10%
- PI3K/AKT/mTOR signaling in cancer 6
- Cell death mechanisms and regulation 1
Genetics top 10%
Oncology top 10%
Pathology and Forensic Medicine
- Cancer Mechanisms and Therapy 3
Pulmonary and Respiratory Medicine
- Renal cell carcinoma treatment 2
Organic Chemistry
- Quinazolinone synthesis and applications 2
Rheumatology
- Rheumatoid Arthritis Research and Therapies 2
Ecology, Evolution, Behavior and Systematics
- Fungal Plant Pathogen Control 1
Cardiology and Cardiovascular Medicine
- Viral Infections and Immunology Research 1

Co-authors: Allan J. Pantuck Arie S. Belldegrun Robert A. Figlin Timothy E. O’Toole David B. Seligson John T. Leppert Ramon Parsons Katrina Podsypanina
Cited by: Hematology Cancer Research Molecular Biology
Journals: Journal of Clinical Oncology (2 papers)Journal of Medicinal Chemistry (2 papers)Molecular Cancer Therapeutics (1 paper)
Partner nations: United States United Kingdom Australia

In The Last Decade

Jay Gibbons

14 papers receiving 1.4k citations

Peers

Countries citing papers authored by Jay Gibbons

Since Specialization

Citations

This map shows the geographic impact of Jay Gibbons's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jay Gibbons with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jay Gibbons more than expected).

Fields of papers citing papers by Jay Gibbons

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jay Gibbons. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jay Gibbons. The network helps show where Jay Gibbons may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Jay Gibbons, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Jay Gibbons Line = papers co-authored together Jay Gibbons links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

14 of 14 papers shown

#	Work
1	A phase I trial of X-396, a novel ALK inhibitor, in patients with advanced solid tumors. Journal of Clinical Oncology ·Leora Horn,Jeffrey R. Infante,George R. Blumenschein,Heather A. Wakelee,Hendrik‐Tobias Arkenau,Gary Dukart,Chris Liang,Kimberly Harrow,Jay Gibbons,Christine M. Lovly,William Pao	2014	28
2	Phase I, first-in-human trial of an oral VEGFR tyrosine kinase inhibitor (TKI) x-82 in patients (pts) with advanced solid tumors. Journal of Clinical Oncology ·Kathleen N. Moore,Suzanne F. Jones,Carla Kurkjian,Hendrik‐Tobias Arkenau,Jeffrey R. Infante,Shubham Pant,Howard A. Burris,D. Scott McMeekin,Jay Gibbons,Kimberly Harrow,Chris Liang,Sara Ramsey,Johanna C. Bendell	2012	6
3	Antitumor Efficacy Profile of PKI-402, a Dual Phosphatidylinositol 3-Kinase/Mammalian Target of Rapamycin Inhibitor Molecular Cancer Therapeutics ·Robert Mallon,Irwin Hollander,Larry Feldberg,Judy Lucas,Veronica Soloveva,Aranapakam M. Venkatesan,Christoph M. Dehnhardt,Efren Delos Santos,Zecheng Chen,Osvaldo dos Santos,Semiramis Ayral‐Kaloustian,Jay Gibbons	2010	52
4	Novel imidazolopyrimidines as dual PI3-Kinase/mTOR inhibitors Bioorganic & Medicinal Chemistry Letters ·Aranapakam M. Venkatesan,Christoph M. Dehnhardt,Zecheng Chen,Efren Delos Santos,Osvaldo dos Santos,Matthew G. Bursavich,A. Gilbert,John W. Ellingboe,Semiramis Ayral‐Kaloustian,Gulnaz Khafizova,Natasja Brooijmans,Robert Mallon,Irwin Hollander,Larry Feldberg,Judy Lucas,Ker Yu,Jay Gibbons,Robert T. Abraham,Tarek S. Mansour	2009	23
5	Lead Optimization of N-3-Substituted 7-Morpholinotriazolopyrimidines as Dual Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Inhibitors: Discovery of PKI-402 Journal of Medicinal Chemistry ·Christoph M. Dehnhardt,Aranapakam M. Venkatesan,Efren Delos Santos,Zecheng Chen,Osvaldo dos Santos,Semiramis Ayral‐Kaloustian,Natasja Brooijmans,Robert Mallon,Irwin Hollander,Larry Feldberg,Judy Lucas,Indrasish Ray Chaudhuri,Ker Yu,Jay Gibbons,Robert T. Abraham,Tarek S. Mansour	2009	66
6	Prognostic relevance of the mTOR pathway in renal cell carcinoma Cancer ·Allan J. Pantuck,David B. Seligson,Tobias Klatte,Hong‐Jeng Yu,John T. Leppert,Laurence Moore,Timothy E. O’Toole,Jay Gibbons,Arie S. Belldegrun,Robert A. Figlin	2007	271
7	Phaeosphaeride A, an Inhibitor of STAT3-Dependent Signaling Isolated from an Endophytic Fungus Organic Letters ·Katherine N. Maloney,Wenshan Hao,Jun Xu,Jay Gibbons,Kuen-Ming Shu,Deborah M. Roll,Sean F. Brady,Frank C. Schroeder,Jon Clardy	2006	54
8	350: Characterization of the MTOR Pathway in Renal Cell Carcinoma and its Use in Predicting Patient Selection for Agents Targeting this Pathway The Journal of Urology ·Allan J. Pantuck,David B. Seligson,Hong Wu,George Thomas,Timothy E. O’Toole,Gary Dukart,Jay Gibbons,Arie S. Belldegrun,Robert A. Figlin	2005	8
9	Identification and Characterization of 4-[[4-(2-Butynyloxy)phenyl]sulfonyl]-N-hydroxy-2,2-dimethyl-(3 S)thiomorpholinecarboxamide (TMI-1), a Novel Dual Tumor Necrosis Factor-α-Converting Enzyme/Matrix Metalloprotease Inhibitor for the Treatment of Rheumatoid Arthritis Journal of Pharmacology and Experimental Therapeutics ·Yuhua Zhang,Jun Xu,Jeremy I. Levin,Martin Hegen,Guangde Li,Heidi Robertshaw,Fionula M. Brennan,Terri Cummons,В. Ивасечко,Nichole R. Vansell,Cheryl Nickerson‐Nutter,D. Barone,K M Mohler,Roy A. Black,J.S. Skotnicki,Jay Gibbons,Marc Feldmann,Philip Frost,G R Larsen,Lih‐Ling Lin	2004	74
10	Characterization of (2R, 3S)-2-({[4-(2-butynyloxy)phenyl]sulfonyl}amino)-N,3-dihydroxybutanamide, a potent and selective inhibitor of TNF-α converting enzyme International Immunopharmacology ·Yuhua Zhang,Martin Hegen,Jun Xu,James C. Keith,Guixian Jin,Xuemei Du,Terri Cummons,Barbara J. Sheppard,Linhong Sun,Nancy Blanco Neira,Vikram Rao,Qin Wang,Weixin Xu,Rebecca Cowling,Cheryl Nickerson‐Nutter,Jay Gibbons,J.S. Skotnicki,Lih‐Ling Lin,Jeremy I. Levin	2004	48
11	In vivo antitumor effects of the mTOR inhibitor CCI-779 against human multiple myeloma cells in a xenograft model Blood ·Patrick Frost,Farhad Moatamed,Bao Hoang,Yijiang Shi,Joseph Gera,Huajun Yan,Philip Frost,Jay Gibbons,Alan Lichtenstein	2004	155
12	Optimization of 4-Phenylamino-3-quinolinecarbonitriles as Potent Inhibitors of Src Kinase Activity Journal of Medicinal Chemistry ·Diane H. Boschelli,Fei Ye,Yanong D. Wang,Minu Dutia,Steve Johnson,Biqi Wu,Karen Miller,Dennis Powell,Miguel Cristóbal Silva Patiño,Mairead Young,Mark Tischler,Kim Arndt,Carolyn Discafani,Moranne Eidelman-Rothman,Jay Gibbons,S H Ohno,Judy Lucas,Jennifer M. Weber,Frank Boschelli	2001	179
13	An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity inPten^+/−mice Proceedings of the National Academy of Sciences ·Katrina Podsypanina,Richard Lee,Bugra,Yorix Frans Detro Wendi,冷王,Janusz Puc,Mehran S. Neshat,Hong Wang,Lin Yang,Jay Gibbons,Minguetti-Câmara Vania Cibele,Valley Dreisbach,John Blenis,Zbigniew Gaciong,Peter Fisher,Charles L. Sawyers,Seiji Kusaka,Ramon Parsons	2001	494
14	Diphosphopyridine nucleotide and the respiration of rat-liver-cell suspensions Biochimica et Biophysica Acta ·Jay Gibbons,K.G. Rienits	1961	7

About Jay Gibbons

Jay Gibbons is a scholar working on Pathology and Forensic Medicine, Hematology, Clinical Biochemistry, Small Animals and Cancer Research, having authored 14 papers that have together received 1.5k indexed citations. Recurring topics across this work include PI3K/AKT/mTOR signaling in cancer (6 papers), Cancer Mechanisms and Therapy (3 papers), Renal cell carcinoma treatment (2 papers), Quinazolinone synthesis and applications (2 papers), Rheumatoid Arthritis Research and Therapies (2 papers), Fungal Plant Pathogen Control (1 paper), Viral Infections and Immunology Research (1 paper) and Cell death mechanisms and regulation (1 paper). The work is most often cited by research in Hematology (193 citations), Cancer Research (243 citations), Molecular Biology (1.1k citations), Genetics (156 citations) and Oncology (358 citations). Jay Gibbons has collaborated with scholars based in United States, United Kingdom and Australia. Frequent co-authors include Allan J. Pantuck, Arie S. Belldegrun, Robert A. Figlin, Timothy E. O’Toole, David B. Seligson, John T. Leppert, Ramon Parsons, Katrina Podsypanina, Valley Dreisbach and Laurence Moore. Their work appears in journals such as Journal of Clinical Oncology, Journal of Medicinal Chemistry, Molecular Cancer Therapeutics, Journal of Pharmacology and Experimental Therapeutics and Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact